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This Editorial announces a new section in the Journal of Translational Medicine: Patient-Targeted Molecular
Therapies. This section is dedicated to the dissemination of targeted molecular therapies in context of patient-
centered outcomes research and evidence-based clinical decisions. The focus on patient-targeted molecular
therapies – spanning small molecules and biomolecules alike – stems from the unprecedented growth in this
arena. This is consonant with the overall objective of the Journal of Translational Medicine, which seeks out to
expand firmly to other vast areas of medicine in the domain of translational science, viewed here as the transaction
between translational research and translational effectiveness. As we inaugurate this new section in Journal of
Translational Medicine, with its mission described in detail in this Editorial, we invite interested scientists to submit
their work for publication.Analyses of current limitations and deficiencies in health
care in the context of the Affordable care Act, signed
into law by President Obama in March 2010 [1], indicate
that national and global trends for the next decades will
emphasize patient-centered outcomes research of
molecular-targeted evidence-based interventions. Treat-
ment modalities in medicine, nursing and dentistry will
be increasingly called upon, and designed to coalesce
translational research - going from the patient to the la-
boratory bench and back to the patient (NIH definition)
- with translational effectiveness - integrating the best
available evidence for optimizing evidence-based health
care interventions in specific clinical settings (AHRQ
definition).
There has been unparalleled and continuous progress
in research and development in broad areas of molecular
medicine resulting in novel platform technologies, drugs,
biomolecules and companion diagnostics on the market
and in development. Additionally, post-approval testing
of novel medicines or therapeutic combinatorial modal-
ities with the aim to improve the standard of care has
been a steady continuous source of information with* Correspondence: fchiappelli@dentistry.ucla.edu
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dynamism of this process, and the magnitude and com-
plexity of resulting informational output, warranting it-
erative application of appropriate research and
evaluation tools across entire domains of medicine, to
identify and promote standard of care or outline state of
the art.
Therefore, innovative models of evidence-based
patient-centered molecular-targeted interventions are
timely and critical. Evidence-based medicine/dentistry/
nursing, through the process of comparative efficacy and
effectiveness research and review for clinical practice
(CEERAP) pursues the identification of the best available
evidence gained from the scientific method to clinical
decision-making [2,3]. CEERAP seeks to assess the
strength of evidence in terms both of what works in a
clinical setting (efficacy), and of the risks, costs and ben-
efits of treatments and diagnostics (effectiveness). Meth-
odologically, CEERAP involves research synthesis across
all the available published studies and “gray” literature
scientific sources that pertain to the specific clinical or
diagnostic question defined by the patient (P), the inter-
ventions (I) under consideration (C) for the clinical out-
come (O) sought, often within the constraints of a given
interval of time (T) and clinical setting (S) (hence, the
acronym PICO-TS). CEERAP is a systematic process of
research that follows the hypothesis-driven scientific
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in a systematic review are analyzed statistically by various
means that include acceptable sampling analysis and
meta-analysis. Not all systematic reviews are so struc-
tured as to incorporate a meta-analysis, and not all meta-
analysis reports are set up and organized as a systematic
PICO-TS research. Systematic reviews and meta-analysis
reports in the context of CEERAP converge to seeking a
consensus of the best available evidence for clinical rele-
vance. Calls for dissemination of this novel approach to
health care are also increasingly pressing.
In response to this urgency, the Journal of Transla-
tional Medicine now inaugurates a new section, entitled
Patient-Targeted Molecular Therapies, which is dedi-
cated to the dissemination of targeted molecular therap-
ies in the context of patient-centered outcomes research
and evidence-based clinical decisions. Therefore, the
focus on patient-targeted molecular therapies – span-
ning small molecules and biomolecules alike – stems
from the unprecedented growth in this arena, fueled by
scientific progress in understanding the molecular
pathogenesis of disease.
The section Patient-Targeted Molecular Therapies pro-
vides avenues for the discussion of translational effect-
iveness pertaining to diverse therapeutic areas including
inflammation, degenerative disorders, cancer, infection,
metabolism, neurologic, cardiovascular to genetic disor-
ders. The section considers pathologies that pertain to
the micro-environment and local immunoregulation and
epigenetics, as well as systems immunophysiology. The
section addresses chronic and acute immune-related
pathologies, from autoimmune disease, to HIV/AIDS,
from immune deficiencies to osteo-immunopathology,
from inborn errors of immune metabolism to psycho-
neuroendocrine-immune pathologies. This section also
considers non-immunological disorders, and conditions
that are at the interface with immunopathology with
both facets: the drug (or therapeutic intervention) and
the companion biomarkers.
The purpose of this new section is consonant with the
overall objective of the Journal of Translational Medi-
cine, which – with traditional and diligent interest in im-
mune therapies - seeks out to expand firmly to other
vast areas of medicine. This section on Patient-Targeted
Molecular Therapies will be complemented by an inter-
est in prognostic and predictive biomarkers, as well as
companion diagnostics as they are a critical tool in the
assessment or application of molecular targeted thera-
peutics, and emphasize patient-targeted research for
personalized medicine, now subsumed under the ter-
minology “patient-centered outcomes research”. As
molecular targeted therapies – through an increased
potential for clinical benefit and data-rich clinical
design - carry the benefit of yielding informative datasets in individual patients during smaller trials in
early development, a focus will be to outline emer-
ging evidence of efficacy or toxicity for innovative
drug candidates.
In brief, as the informational output regarding more
mature or approved molecular targeted therapies evolves
across multiple development programs and studies, the
specific content of this section will include research pro-
ducts in the form of systematic reviews, clinically rele-
vant complex systematic reviews and meta-analyses. It
will also include reviews of the best available evidence,
in the form of critical evidence reviews and evidence-
based policies. The scientific focus of this section on
Patient-Targeted Molecular Therapies in Journal of
Translational Medicine specifically addresses the best
available evidence about the translational effectiveness
of biomarkers-guided targeted molecular therapies of
established medical and dental clinical conditions.
With this opening editorial, we announce and inaugur-
ate this new section in Journal of Translational Medi-
cine. We invite interested scientists to submit their work
for publication.
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